Four SPORE Grants Will Support Ovarian Cancer Research

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 8 No 12
Volume 8
Issue 12

BETHESDA, Md-Four institutions have received SPORE (Specialized Program of Research Excellence) grants from the NCI for ovarian cancer research. The grants, totaling $5.85 million for the first year, went to:

BETHESDA, Md—Four institutions have received SPORE (Specialized Program of Research Excellence) grants from the NCI for ovarian cancer research. The grants, totaling $5.85 million for the first year, went to:

The University of Texas M.D. An-derson Cancer Center, to pursue chemo-prevention, antiangiogenesis, and novel treatments for the disease.

Fred Hutchinson Cancer Research Center, to establish the Pacific Ovarian Cancer Research Consortium, whose efforts will include studies of genes responsible for resistance to chemotherapy and the development of a nucleic acid vaccine for prevention of the disease.

Fox Chase Cancer Center, to develop an interdisciplinary ovarian cancer program focused on carcinogenesis, prevention, and treatment of the cancer.

The University of Alabama at Birmingham, for the development of a new genetically engineered monoclonal antibody therapy, targeted immunotherapy, and research to find markers of disease progression that can be used as targets for chemoprevention.

Recent Videos
Oncologists are still working on management strategies for neuropathy; a common adverse effect related to chemotherapeutics for ovarian cancer.
Genetic testing information can be used to risk-stratify ovarian cancer survivors for breast cancer, particularly those with BRCA1 or BRCA2 mutations.
Genetic testing for ovarian cancer may help inform treatment decisions for patients with advanced disease, particularly regarding PARP inhibitor use.
Future findings from a translational analysis of the OVATION-2 trial may corroborate prior clinical data with IMNN-001 in advanced ovarian cancer.
Approximately 10% of patients discontinued treatment with avutometinib/defactinib due to toxicity in the phase 2 RAMP 201 trial.
Response rates appeared to be higher with avutometinib plus defactinib vs avutometinib alone in the phase 2 RAMP 201 study.
Patients who respond to avutometinib/defactinib may be maintained on treatment for long periods of time, says Rachel N. Grisham, MD.
Findings from the OVARIO study show that patients with HRR–deficient and BRCA-mutated disease benefitted the most from niraparib/bevacizumab maintenance.
Related Content